Results 31 to 40 of about 549,379 (280)

Continuous Activity Monitoring During Concurrent Chemoradiotherapy [PDF]

International Journal of Radiation Oncology*Biology*Physics, 2017
To perform a prospective trial testing the feasibility and utility of acquiring activity data as a measure of health status during concurrent chemoradiotherapy.Ambulatory patients who were planned for treatment with concurrent chemoradiotherapy with curative intent for cancers of the head and neck, lung, or gastrointestinal tract were provided with ...
William Bodner, Nitin Ohri, Keyur J. Mehta, Chandan Guha, Madhur Garg, Rafi Kabarriti, Shalom Kalnicki, Viswanathan Shankar, Balazs Halmos, Missak Haigentz, Bruce D. Rapkin   +10 more
openaire   +2 more sources

The Impact of Active Nutritional Support for Head and Neck Cancer Patients Receiving Concurrent Chemoradiotherapy

Siriraj Medical Journal, 2019
Objective: Malnutrition is the most common problem in head and neck cancer (HNC) patients receiving concurrent chemoradiotherapy. The radiation toxicities cause decreased food intake, with resultant severe weight loss and malnutrition.
Vutisiri Veerasarn, Nattapatch Janhom, Yaowalak Chansilpa, Nan Suntornpong, Kullathorn Thephamongkhol, Nantakan Apiwarodom, Janjira Petsuksiri, Pittaya Dankulchai, Jiraporn Setakornnukul, Achiraya Teyateeti, Warissara Rongthong, Panid Chaysiri   +11 more
doaj   +1 more source

Endostar (rh‐endostatin) improves efficacy of concurrent chemoradiotherapy for locally advanced non‐small cell lung cancer: A systematic review and meta‐analysis

Thoracic Cancer, 2021
We aimed to clarify the benefits of the addition of rh‐endostatin into concurrent chemoradiotherapy (CCRT) versus CCRT alone for locally advanced non‐small cell lung cancer (NSCLC) by a meta‐analysis.
M. Yuan, Y. Zhai, Y. Men, Jianyang Wang, L. Deng, Wenqing Wang, Y. Bao, Xu Yang, Shuang Sun, Zeliang Ma, Yun-Bao Liu, Jun Wang, Hui Zhu, Z. Hui   +13 more
semanticscholar   +1 more source

Hematological Toxicities of Concurrent Chemoradiotherapies in Head and Neck Cancers: Comparison Among Cisplatin, Nedaplatin, Lobaplatin, and Nimotuzumab

Frontiers in Oncology, 2021
BackgroundCisplatin-based concurrent chemoradiotherapy is standard of care for locally advanced head and neck cancers (LAHNC). Nedaplatin, lobaplatin and nimotuzumab have shown anti-cancer effect with less gastrointestinal toxicity and nephrotoxicity ...
Qiuji Wu, Chunmei Zhu, Shuyuan Zhang, Yunfeng Zhou, Yahua Zhong   +4 more
doaj   +1 more source

Severe Pulmonary Toxicity With Concurrent Anlotinib and Chemoradiotherapy in Stage III NSCLC: The ALTER-L042 Phase 1 Clinical Trial

JTO Clinical and Research Reports, 2022
Introduction: Anlotinib has brought about marked progression-free survival and overall survival benefit compared with placebos as third-line or further treatment in advanced NSCLC.
Hui Zhu, MD, Wenxiao Jia, PhD, Xuquan Jing, MD, Wei Huang, MD, Linlin Wang, MD, Jinming Yu, MD   +5 more
doaj  

Neoadjuvant chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy followed by adjuvant chemotherapy in locally advanced nasopharyngeal carcinoma [PDF]

BMC Cancer, 2018
Concurrent chemoradiotherapy followed by adjuvant chemotherapy (CCRT-AC) is currently recommended as the standard treatment for locally advanced nasopharyngeal carcinoma (LA-NPC). Neoadjuvant chemotherapy followed by concurrent chemoradiotherapy (NAC-CCRT) is an alternative strategy for decreasing tumor size and controlling micrometastases before main ...
Jiraporn Setakornnukul, Kullathorn Thephamongkhol   +1 more
openaire   +3 more sources

Addition of chemoradiotherapy to palliative chemotherapy in de novo metastatic nasopharyngeal carcinoma: a real-world study

Cancer Cell International, 2022
Background To determine whether concurrent chemotherapy is necessary during locoregional radiotherapy (RT) after palliative chemotherapy (PCT) in patients with de novo metastatic nasopharyngeal carcinoma (mNPC).
Shuo-Han Zheng, Yu-Tong Wang, Song-Ran Liu, Zi-Lu Huang, Guan-Nan Wang, Jin-Tao Lin, Shi-Rong Ding, Chen Chen, Yun-Fei Xia   +8 more
doaj   +1 more source

Concurrent chemoradiotherapy for esophageal carcinoma patients with malignant fistulae [PDF]

Cancer, 1999
It remains controversial whether chemotherapy and/or radiotherapy are/is contraindicated for esophageal carcinoma patients with malignant fistulae. In some case reports, closure of fistulae by chemotherapy or radiotherapy has been reported. The current study investigated chemoradiotherapy for these patients using various primary treatments to manage ...
Shigeaki Yoshida, Narikazu Boku, Manabu Muto, Shin-ichi Miyamoto, Atsushi Ohtsu, Satoshi Ishikura, Hisao Tajiri, Takashi Ogino, Mitsuo Satake, Kei Muro   +9 more
openaire   +3 more sources

A retrospective study of pegylated recombinant human granulocyte colony-stimulating factor (PEG-rhG-CSF) in preventing neutropenia during definitive concurrent chemoradiotherapy in patients with esophageal squamous carcinoma

Radiation Medicine and Protection, 2022
Objective: To compare the efficacy and safety of pegylated recombinant human granulocyte colony-stimulating factor (PEG-rhG-CSF) for preventive or delayed treatment in neutropenia, completion rate of concurrent chemoradiotherapy and hospitalization rate ...
Xin Dong, Wei Deng, Leilei Jiang, Dan Yang, Huiming Yu, Dongming Li, Anhui Shi, Rong Yu, Weihu Wang   +8 more
doaj  

Prognosis of Stage ⅠB-ⅡA Cervical Squamous Cell Carcinoma Patients with Intermediate Risk Factors Treated with Adjuvant Chemotherapy Versus Concurrent Chemoradiotherapy: A Prospective Randomized Controlled Trial

Zhongliu Fangzhi Yanjiu, 2021
Objective To compare the prognosis of stage ⅠB-ⅡA cervical squamous cell carcinoma patients with intermediate risk factrs between adjuvant chemotherapy and concurrent chemoradiotherapy, and to explore the safety and effectiveness of adjuvant chemotherapy
PAN Zhongmian, CHEN Qi, LI Li
doaj   +1 more source